Pipeline - HANGZHOU DAC BIOTECHNOLOGY CO.,LTD

Pipeline

As an enterprise focusing on ADC drug innovation and production, DAC Biotechnology has independently established a complete technology platform in the ADC field.

It has the capabilities of new ADC drug research and development, as well as process development.

Product

DX126-262（PRC）
DX126-262（USA）
DAC-002（PRC）
DAC-002（USA）
DXC003
DXC004A
DXC-005
DXC-006
DXC007
DXC008
DXC009
DXC010
DXC011
DXC012
DXC013
DXC014
DXC015
DXC016
DXC017
DXC020
DXC019
DXC018

10 months
3 months
18 months
18 months
24 months
10 months

Target

Indication

Pre-clinical Development
Drug safety evaluation
IND Approval
Phase I Study
Phase II Study
Phase III Study
BLA

HER-2

Breast/Gastric cancer
HER-2

Breast/Gastric cancer
Trop-2

TNBC/SCLC
Trop-2

TNBC/SCLC
Trop-2

TNBC/SCLC
xxx

Lung cancer, head & neck tumors
Muc-1

Colorectal/Pancreatic cancer
xxx

Lung cancer
xxx

Leukemia
xxx

Solid tumors
xxx

Multiple myeloma
xxx

Solid tumors
xxx

Solid tumors
xxx

Solid tumors
xxx

Solid tumors
xxx

Solid tumors
xxx

Solid tumors
xxx

Solid tumors
xxx

Solid tumors
XXXX

Solid tumors
XXXX

Solid tumors
XXXX

Solid tumors

HANGZHOU DAC BIOTECHNOLOGY CO .,LTD

Address

Building 12, No. 260 Sixth Street, ?ZhengTaiZhongZi Sci &Tech Park, HEDA， ?Hangzhou, ?Zhejiang 310018, China
Telephone

0571-56050590
Email

duoxi@dacbiotech.com

Official accounts

Links

Center For DRUG EVALUTION NMPA